Considering both randomized controlled trials and cohort studies, the study results underscore that progression-free survival can increase significantly, emphasizing the potential therapeutic benefits of PD-1 and PD-L1 inhibitors for salivary gland cancer patients. The gene discussed is CD274; the disease is salivary gland cancer.